Amino acid compositions for the amelioration of symptoms of environmental enteropathy
The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of symptoms of a disease selected from the group consisting of: Ebola virus infection, HIV infection, ataxia, environmental enteropathy, cancer, hangover, inflammatory disease, and porcine epidemic diarrhea. In preferred embodiments, the composition includes a combination of one or more amino acids selected from the group comprising lysine, aspartic acid, glycine, isoleucine, threonine, tyrosine, valine, tryptophan, asparagine and/or serine.
1. A method for ameliorating symptoms of environmental enteropathy in a subject in need thereof comprising:
administering to the subject in need thereof, an effective amount of a formulation comprising free amino acids, wherein the free amino acids consist essentially of:
free amino acids of aspartic acid, valine, serine, threonine, and tyrosine; and
optionally electrolytes, vitamins, or minerals, or any combination thereof;
wherein the formulation does not comprise:
free amino acid glutamine;
a glutamine-containing dipeptide; or
any combination thereof;
or, when free amino acid glutamine, a glutamine-containing dipeptide, or any combination thereof is present, the free amino acid glutamine, the glutamine-containing dipeptide, or any combination thereof is present at a concentration less than 300 mg/1;
wherein the formulation does not comprise glucose;
or, when glucose is present, glucose is present at a concentration of less than 1 g/1; and
wherein the formulation does not comprise:
free amino acid methionine;
a methionine-containing dipeptide; or
any combination thereof;
or, when free amino acid methionine, a methionine-containing dipeptide, or any combination thereof is present, the free amino acid methionine, the methionine-containing dipeptide, or any combination thereof is present at a concentration less than 300 mg/1; and
wherein the effective amount of the formulation is sufficient to ameliorate symptoms of environmental enteropathy in the subject.
2. The method of claim 1 , wherein the free amino acids consist of free amino acids of aspartic acid, valine, serine, threonine, and tyrosine.
3. The method of claim 1 , wherein the formulation is formulated for oral administration.
4. The method of claim 1 , wherein the formulation is administered through enteral feeding.
5. The method of claim 1 , wherein the formulation is administered parenterally.
6. The method of claim 1 , wherein the formulation is administered in pill form.
7. The method of claim 1 , wherein aspartic acid is at a concentration of between 532 to 4792 mg/1.
8. The method of claim 1 , wherein valine is at a concentration of between 469 to 4217 mg/1.
9. The method of claim 1 , wherein serine is at a concentration of between 420 to 3784 mg/1.
10. The method of claim 1 , wherein threonine is at a concentration of between 476 to 4288 mg/1.
11. The method of claim 1 , wherein tyrosine is at a concentration of between 725 to 6523 mg/1.
12. The method of claim 1 , wherein aspartic acid is at a concentration of between 532 to 4792 mg/1, valine is at a concentration of between 469 to 4217 mg/1, serine is at a concentration of between 420 to 3784 mg/1, threonine is at a concentration of between 476 to 4288 mg/1, and tyrosine is at a concentration of between 725 to 6523 mg/1.
13. The method of claim 1 , wherein symptoms of environmental enteropathy selected from the group consisting of: malabsorption, diarrhea, nausea, vomiting, electrolyte imbalance, dehydration, and any combinations thereof.
14. The method of claim 13 , wherein symptoms of environmental enteropathy comprises malabsorption of food, nutrients, vitamins, minerals, or combinations thereof.